Premium
Retrospective analysis of the real‐world utilization of ranibizumab in wAMD
Author(s) -
TADAYONI R,
HOLZ F,
HEAH TGH,
HELDNER S,
THE AURA STEERING COMMITTEE FOR
Publication year - 2012
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2012.3666.x
Subject(s) - ranibizumab , medicine , optometry , chemotherapy , bevacizumab
Purpose With monthly ranibizumab treatment for wet AMD (wAMD), optimal functional outcomes are achieved. To reduce management burdens, as‐needed dosing regimens have been explored. AURA study examines real‐world utilization of ranibizumab. Methods Retrospective, international (Canada, France, Germany, Ireland, Italy, Netherlands, UK, Venezuela), non‐interventional, observational study. Target enrollment is 444 patients per country and will be completed by September 2012. Consecutive AMD patients prescribed ranibizumab by their physicians will be included, with a follow‐up period of up to 2.5 years. Primary outcomes are (1) change in visual acuity and (2) resource utilization (number of treatment and monitoring visits, treatment use). Descriptive statistics will be used. Results Results for Germany are already available: 916 patients from 28 sites were screened. Of these, 462 (50.4%) were not enrolled. The reasons (not mutually exclusive) included no written informed consent (n=349), consent obtained after target patient number reached (n=68), use of non‐conventional interventions (n=21), ranibizumab use did not start between January‐August 2009 (n=23), and no wAMD diagnosis (n=6). Of the 454 enrolled, 437 (96.3%) received ≥1 ranibizumab dose. Of the 437, most were women (n=260, 59.5%), Caucasian (n=368, 84.2%), and initiated treatment at ≥75 years of age (n=304, 69.6%). Mean age was 79.2±8.1 years. Conclusion These data will provide valuable insight into resource utilization patterns and their effects on visual outcome in various ranibizumab‐treated wAMD patient populations.Commercial interest